Capital Research Global Investors’ Q3 Healthcare Stock Allocations

Wall St. Watchdog reveals information regarding Capital Research Global Investors’ top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 48 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $23.942 billion.

  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Capital Research Global Investors reported holding 63,648,207 shares with a market value of $3,349,168,584. This comprised 1.34% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 67,990,207 shares with a market value of $3,477,019,144. This comprised 1.71% of the total portfolio. The net change in shares for this position over the two quarters is 4,342,000. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Capital Research Global Investors reported holding 109,681,756 shares with a market value of $3,870,669,270. This comprised 1.55% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 94,734,270 shares with a market value of $3,097,810,701. This comprised 1.52% of the total portfolio. The net change in shares for this position over the two quarters is -14,947,486. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, Capital Research Global Investors reported holding 31,958,167 shares with a market value of $1,864,758,996. This comprised 0.75% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 33,948,592 shares with a market value of $1,865,814,585. This comprised 0.92% of the total portfolio. The net change in shares for this position over the two quarters is 1,990,425. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Biogen Idec Inc. (NASDAQ:BIIB): On 06/30/2011, Capital Research Global Investors reported holding 21,514,897 shares with a market value of $2,300,372,748. This comprised 0.92% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 17,700,400 shares with a market value of $1,648,792,287. This comprised 0.81% of the total portfolio. The net change in shares for this position over the two quarters is -3,814,497. About Company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Capital Research Global Investors reported holding 41,337,500 shares with a market value of $1,197,133,962. This comprised 0.48% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 41,337,500 shares with a market value of $1,297,170,715. This comprised 0.64% of the total portfolio. The net change in shares for this position over the two quarters is 0. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Allergan Inc. (NYSE:AGN): On 06/30/2011, Capital Research Global Investors reported holding 12,885,000 shares with a market value of $1,072,676,250. This comprised 0.43% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 12,995,000 shares with a market value of $1,070,528,064. This comprised 0.53% of the total portfolio. The net change in shares for this position over the two quarters is 110,000. About Company: Allergan, Inc. is a multi-specialty health care company that discovers, develops and commercializes pharmaceuticals, biologics and medical devices. The Company develops products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, Capital Research Global Investors reported holding 26,081,000 shares with a market value of $1,080,014,206. This comprised 0.43% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 26,438,766 shares with a market value of $1,025,824,101. This comprised 0.5% of the total portfolio. The net change in shares for this position over the two quarters is 357,766. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
  • Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): On 06/30/2011, Capital Research Global Investors reported holding 22,376,800 shares with a market value of $1,079,009,323. This comprised 0.43% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 26,971,800 shares with a market value of $1,003,890,429. This comprised 0.49% of the total portfolio. The net change in shares for this position over the two quarters is 4,595,000. About Company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.
  • St. Jude Medical Inc. (NYSE:STJ): On 06/30/2011, Capital Research Global Investors reported holding 22,458,000 shares with a market value of $1,070,797,447. This comprised 0.43% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 23,173,000 shares with a market value of $838,630,838. This comprised 0.41% of the total portfolio. The net change in shares for this position over the two quarters is 715,000. About Company: St. Jude Medical, Inc. develops, manufactures, and distributes medical devices for the worldwide cardiovascular market. The Company serves patients and its health care customers with products and services including heart valves, cardiac rhythm management systems, specialty catheters, and other cardiovascular devices.
  • Alexion Pharmaceuticals Inc. (NASDAQ:ALXN): On 06/30/2011, Capital Research Global Investors reported holding 11,950,000 shares with a market value of $562,008,485. This comprised 0.22% of the total portfolio. On 09/30/2011, Capital Research Global Investors reported holding 12,455,000 shares with a market value of $797,867,270. This comprised 0.39% of the total portfolio. The net change in shares for this position over the two quarters is 505,000. About Company: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.

(Note: Data regarding Capital Research Global Investors’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>